MidWestOne Financial Group Inc. Buys 4,559 Shares of Jazz Pharmaceuticals PLC $JAZZ

MidWestOne Financial Group Inc. lifted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 13.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,271 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,559 shares during the quarter. Jazz Pharmaceuticals comprises about 0.6% of MidWestOne Financial Group Inc.’s investment portfolio, making the stock its 27th biggest position. MidWestOne Financial Group Inc. owned about 0.06% of Jazz Pharmaceuticals worth $5,176,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in JAZZ. Vestal Point Capital LP purchased a new position in Jazz Pharmaceuticals during the 2nd quarter valued at approximately $127,344,000. AQR Capital Management LLC boosted its position in shares of Jazz Pharmaceuticals by 62.1% during the 2nd quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock valued at $84,341,000 after acquiring an additional 304,463 shares during the last quarter. Allianz Asset Management GmbH grew its holdings in shares of Jazz Pharmaceuticals by 453.9% in the second quarter. Allianz Asset Management GmbH now owns 325,403 shares of the specialty pharmaceutical company’s stock valued at $34,532,000 after purchasing an additional 266,658 shares in the last quarter. Wedge Capital Management L L P NC bought a new stake in Jazz Pharmaceuticals in the third quarter worth $27,834,000. Finally, Goldman Sachs Group Inc. increased its position in Jazz Pharmaceuticals by 147.7% in the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after purchasing an additional 209,667 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Up 0.0%

Shares of NASDAQ JAZZ opened at $166.31 on Friday. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $182.99. The firm has a 50-day simple moving average of $167.60 and a two-hundred day simple moving average of $147.00. The company has a market cap of $10.10 billion, a P/E ratio of -27.40, a PEG ratio of 0.89 and a beta of 0.26. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Bank of America increased their price objective on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Wells Fargo & Company lifted their price target on Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Morgan Stanley reissued an “overweight” rating and set a $225.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, January 8th. Finally, Royal Bank Of Canada set a $194.00 price objective on Jazz Pharmaceuticals and gave the company an “outperform” rating in a research note on Monday, November 17th. Fourteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $205.67.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Rick E. Winningham sold 5,500 shares of the company’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $180.86, for a total value of $994,730.00. Following the transaction, the director owned 8,893 shares of the company’s stock, valued at $1,608,387.98. This represents a 38.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Bruce C. Cozadd sold 77,500 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $177.81, for a total value of $13,780,275.00. Following the sale, the director owned 393,332 shares of the company’s stock, valued at approximately $69,938,362.92. This trade represents a 16.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 123,791 shares of company stock worth $21,991,850 over the last quarter. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.